标题：奈必洛尔治疗高血压的研究进展

      作者：朱 海 综述 1，王志禄 审校 2
    （1.兰州大学第一临床医学院，甘肃 兰州 730000；
2.兰州大学第一医院心内科，甘肃 兰州 730000）

      卷次： 2015年26卷8期

      【摘要】 高血压(Hypertension)是严重损害人类健康的危险因素，是导致患者就诊的常见原因，预计至2020
年，它将成为人类主要的公共健康问题，因此，将血压控制在正常范围内至关重要。奈必洛尔是第三代β受体阻
滞剂，因其降压效果好，不影响血糖、血脂代谢，不良反应少，独特的扩张血管作用，以及高度的β1受体选择性，被
推荐用于高血压的治疗。目前，国内外对其治疗高血压有效性及安全性做了很多的研究，本文就其在高血压的
治疗方面应用的研究进展加以综述。

      【关键词】 奈必洛尔；高血压；β受体阻滞剂；治疗；进展

      【中图分类号】 R544.1 【文献标识码】 A 【文章编号】 1003—6350（2015）08—1176—04


Research progress of Nebivolol in the treatment of hypertension.
ZHU Hai 1, WANG Zhi-lu 2. 1. The First Clinical
Medicine College, Lanzhou University, Lanzhou 730000, Gansu, CHINA; 2. Department of Cardiology, the First Hospital of
Lanzhou University, Lanzhou 730000, Gansu, CHINA
【Abstract】 Hypertension, one of the most common diseases, is a risk factor that seriously damage the health
of people. It is anticipated that in the year of 2020, hypertension will become the main public health problem. There-
fore, it is vital to keep the blood pressure in the normal range. Nebivolol, a third-generation β-blocker, has been recom-
mended to treat hypertension because of its efficacy in the treatment of hypertension, no influence in the metabolic of
blood sugar and lipid, less occurrence of adverse reactions, unique vasodilator properties, and highly selectivity of the
β1 receptor. Up to now, there are many studies about the effectiveness and tolerability of Nebivolol in the treatment of
hypertension. This review is going to summarize the research progress in the field.

      【Key words】 Nebivolol; Hypertension; β-blockers; Treatment; Research progress
·综 述·